300406 九强生物
已收盘 04-10 15:00:00
资讯
新帖
简况
九强生物（300406）披露获得2项发明专利证书公告，4月3日股价下跌3.05%
证券之星 · 04-03
九强生物（300406）披露获得2项发明专利证书公告，4月3日股价下跌3.05%
九强生物(300406.SZ)子公司取得多项医疗器械注册证
智通财经网 · 03-31
九强生物(300406.SZ)子公司取得多项医疗器械注册证
九强生物（300406）披露获得2项发明专利证书公告，3月26日股价下跌1.62%
证券之星 · 03-26
九强生物（300406）披露获得2项发明专利证书公告，3月26日股价下跌1.62%
3月20日九强生物创60日新低，招商医药健康产业股票基金重仓该股
证券之星 · 03-20
3月20日九强生物创60日新低，招商医药健康产业股票基金重仓该股
股市必读：九强生物（300406）3月19日董秘有最新回复
证券之星 · 03-20
股市必读：九强生物（300406）3月19日董秘有最新回复
九强生物：公司正围绕行业政策、市场格局及技术趋势，对现有检验业务进行全面复盘与战略优化
证券之星 · 03-19
九强生物：公司正围绕行业政策、市场格局及技术趋势，对现有检验业务进行全面复盘与战略优化
九强生物（300406）披露取得医疗器械注册证书公告，3月4日股价下跌2.0%
证券之星 · 03-04
九强生物（300406）披露取得医疗器械注册证书公告，3月4日股价下跌2.0%
九强生物(300406.SZ)取得一项医疗器械注册证书
智通财经 · 03-03
九强生物(300406.SZ)取得一项医疗器械注册证书
九强生物（300406）披露持股5%以上股东减持计划期限届满公告，3月2日股价下跌2.28%
证券之星 · 03-02
九强生物（300406）披露持股5%以上股东减持计划期限届满公告，3月2日股价下跌2.28%
九强生物最新公告：取得白蛋白测定试剂盒医疗器械注册证书
证券之星 · 02-27
九强生物最新公告：取得白蛋白测定试剂盒医疗器械注册证书
九强生物最新公告：取得纤维蛋白（原）降解产物测定试剂盒医疗器械注册证书
证券之星 · 02-09
九强生物最新公告：取得纤维蛋白（原）降解产物测定试剂盒医疗器械注册证书
九强生物(300406.SZ)发预减，预计2025年度归母净利润1.8亿元至2.18亿元，同比下降59.07%至66.21%
智通财经 · 01-28
九强生物(300406.SZ)发预减，预计2025年度归母净利润1.8亿元至2.18亿元，同比下降59.07%至66.21%
九强生物新注册《MDC7600全自动凝血分析仪操作软件V1.0.0.000001》等2个项目的软件著作权
证券之星 · 01-28
九强生物新注册《MDC7600全自动凝血分析仪操作软件V1.0.0.000001》等2个项目的软件著作权
九强生物（300406）披露持股5%以上股东减持致权益变动公告，1月27日股价下跌2.59%
证券之星 · 01-27
九强生物（300406）披露持股5%以上股东减持致权益变动公告，1月27日股价下跌2.59%
1月21日九强生物发布公告，股东减持145.43万股
证券之星 · 01-21
1月21日九强生物发布公告，股东减持145.43万股
九强生物：迈新生物已开始进行海外市场注册体系搭建
证券之星 · 01-12
九强生物：迈新生物已开始进行海外市场注册体系搭建
股市必读：九强生物（300406）1月9日董秘有最新回复
证券之星 · 01-12
股市必读：九强生物（300406）1月9日董秘有最新回复
九强生物：病理AI相关项目处于临床验证阶段
证券之星 · 01-09
九强生物：病理AI相关项目处于临床验证阶段
股市必读：九强生物（300406）1月8日董秘有最新回复
证券之星 · 01-09
股市必读：九强生物（300406）1月8日董秘有最新回复
九强生物（300406）披露取得医疗器械注册证书，1月5日股价上涨3.29%
证券之星 · 01-05
九强生物（300406）披露取得医疗器械注册证书，1月5日股价上涨3.29%
加载更多
公司概况
公司名称：
北京九强生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-30
主营业务：
北京九强生物技术股份有限公司的主营业务是打造多元化、高质量体外诊断检测平台，目前拥有病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。公司的主要产品是病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。2025年1月14日，公司荣获“军事科学技术进步一等奖”。
发行价格：
14.32
{"stockData":{"symbol":"300406","market":"SZ","secType":"STK","nameCN":"九强生物","latestPrice":12.06,"timestamp":1775804616000,"preClose":11.93,"halted":0,"volume":2853300,"delay":0,"changeRate":0.0109,"floatShares":424000000,"shares":586000000,"eps":0.7364,"marketStatus":"已收盘","change":0.13,"latestTime":"04-10 15:00:00","open":11.98,"high":12.18,"low":11.97,"amount":34476900,"amplitude":0.0176,"askPrice":12.07,"askSize":32,"bidPrice":12.06,"bidSize":829,"shortable":0,"etf":0,"ttmEps":0.7364,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":11.93,"symbolType":"stock","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":13.12,"lowLimit":10.74,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":586308628,"isCdr":false,"pbRate":1.83,"roa":"--","peRate":16.376969,"roe":"6.73%","epsLYR":0.92,"committee":0.304212,"marketValue":7071000000,"turnoverRate":0.0067,"status":0,"floatMarketCap":5117000000},"requestUrl":"/m/hq/s/300406","defaultTab":"news","newsList":[{"id":"2624654337","title":"九强生物（300406）披露获得2项发明专利证书公告，4月3日股价下跌3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654337?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:40","pubTimestamp":1775212827,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，九强生物报收于11.78元，较前一交易日下跌3.05%，最新总市值为69.07亿元。该股当日开盘12.1元，最高12.16元，最低11.74元，成交额达3856.16万元，换手率为0.77%。公告显示，公司近期获得2项发明专利证书，分别为丙戊酸检测试剂盒和样本系统。丙戊酸检测试剂盒采用新型丙戊酸衍生物及马来酰亚胺-巯基偶联方法，实现酶与衍生物1:1偶联，降低批间差，具备简便、快捷、低成本特点，适配多种主流自动化设备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0077","300406","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623719309","title":"九强生物(300406.SZ)子公司取得多项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2623719309","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623719309?lang=zh_cn&edition=full","pubTime":"2026-03-31 15:57","pubTimestamp":1774943861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)公告，公司全资子公司福州迈新生物技术开发有限公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品名称为：HER2抗体试剂(免疫组织化学法)、孕激素受体抗体试剂(免疫组织化学法)、CD20抗体试剂(免疫组织化学法)。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0046","BK0239","159883","BK1100","BK1574","BK0077","09996","BK1583","09997","300406","BK0012","BK0028","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622557869","title":"九强生物（300406）披露获得2项发明专利证书公告，3月26日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622557869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622557869?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:31","pubTimestamp":1774535475,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，九强生物报收于11.55元，较前一交易日下跌1.62%，最新总市值为67.72亿元。该股当日开盘11.72元，最高11.82元，最低11.49元，成交额达2964.68万元，换手率为0.6%。九强生物于近日披露《关于公司获得发明专利证书的公告》。公告显示，公司近期获得2项发明专利证书，分别为“酶标记物的制备方法”和“他克莫司检测试剂盒”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","BK0046","BK0012","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786991","title":"3月20日九强生物创60日新低，招商医药健康产业股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786991?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:25","pubTimestamp":1773995146,"startTime":"0","endTime":"0","summary":"证券之星消息，3月20日九强生物创60日新低，收盘报12.02元，当日跌1.72%，换手率0.87%，成交量3.68万手，成交额4462.02万元。重仓九强生物的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为招商基金的招商医药健康产业股票。该公募基金现任基金经理为李佳存。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000027791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","BK0077","BK0046","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620992273","title":"股市必读：九强生物（300406）3月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2620992273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620992273?lang=zh_cn&edition=full","pubTime":"2026-03-20 02:35","pubTimestamp":1773945313,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，九强生物报收于12.23元，下跌2.0%，换手率1.18%，成交量4.99万手，成交额6114.54万元。董秘最新回复投资者： 随着检验立项指南的落地，希望公司能做一个全盘的分析。国内市场规模已经被锁定而且竞争激烈。公司正围绕行业政策、市场格局及技术趋势，对现有检验业务进行全面复盘与战略优化，聚焦资源提升长期竞争力。当日关注点来自交易信息汇总：3月19日主力资金净流出239.77万元，游资资金净流入253.71万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000002246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0077","BK0046","300406","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620979210","title":"九强生物：公司正围绕行业政策、市场格局及技术趋势，对现有检验业务进行全面复盘与战略优化","url":"https://stock-news.laohu8.com/highlight/detail?id=2620979210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620979210?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:15","pubTimestamp":1773908120,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物03月19日在投资者关系平台上答复投资者关心的问题。建议不要再把研发费用投入到常规的生化免疫产品或者生免流水线上了。国内市场规模已经被锁定而且竞争激烈。公司正围绕行业政策、市场格局及技术趋势，对现有检验业务进行全面复盘与战略优化，聚焦资源提升长期竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900025548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","300406","BK0239","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616253364","title":"九强生物（300406）披露取得医疗器械注册证书公告，3月4日股价下跌2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616253364","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616253364?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:13","pubTimestamp":1772615619,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，九强生物报收于12.28元，较前一交易日下跌2.0%，最新总市值为72亿元。该股当日开盘12.45元，最高12.55元，最低12.23元，成交额达5764.52万元，换手率为1.1%。九强生物于近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品名称为血型鉴定及不规则抗体筛查质控品，注册证编号国械注准20263400443，注册类别为Ⅲ类，有效期至2031年3月2日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400029991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1222","BK1100","BK0046","BK1583","09997","BK0239","300406","09996","BK0028","BK0012","BK1574","159883","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616311158","title":"九强生物(300406.SZ)取得一项医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616311158","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616311158?lang=zh_cn&edition=full","pubTime":"2026-03-03 15:46","pubTimestamp":1772523980,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)发布公告，公司于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品名称：总蛋白测定试剂盒(双缩脲法)。该试剂盒用于体外定量测定人血清或血浆中总蛋白(TP)的含量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK1100","BK0046","BK1583","09997","BK0239","300406","09996","BK0028","BK0012","BK1574","159883","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616356571","title":"九强生物（300406）披露持股5%以上股东减持计划期限届满公告，3月2日股价下跌2.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616356571","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616356571?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:05","pubTimestamp":1772463920,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，九强生物报收于12.83元，较前一交易日下跌2.28%，最新总市值为75.22亿元。九强生物于2026年3月2日披露《关于持股5%以上股东减持股份计划期限届满的公告》。自2025年12月11日至2026年1月20日，其通过集中竞价交易方式累计减持公司股份1,454,300股，占公司总股本的0.248%。减持股份来源为首次公开发行前已发行的股份。本次减持已按相关规定履行预披露义务，与此前披露的计划一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0077","BK0239","300406","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614880789","title":"九强生物最新公告：取得白蛋白测定试剂盒医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614880789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614880789?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:31","pubTimestamp":1772181101,"startTime":"0","endTime":"0","summary":"九强生物(300406.SZ)公告称，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为白蛋白测定试剂盒（溴甲酚绿法），注册证编号为京械注准20262400050，注册类别为Ⅱ类，有效期至2031年2月12日。该试剂盒用于体外定量测定人血清和血浆中的白蛋白含量。此注册证的取得丰富了公司产品线，预计对公司未来的经营产生积极影响，但实际销售情况取决于市场推广效果，公司目前无法预测其对未来业绩的具体影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700026532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0239","BK1574","159883","BK0012","BK1222","300406","BK1583","BK1100","09996","09997","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610800226","title":"九强生物最新公告：取得纤维蛋白（原）降解产物测定试剂盒医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610800226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610800226?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:43","pubTimestamp":1770626583,"startTime":"0","endTime":"0","summary":"九强生物公告称，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为纤维蛋白（原）降解产物测定试剂盒，注册证编号为京械注准20262400041，注册类别为Ⅱ类，有效期至2031年2月4日。该试剂盒用于体外定量检测人血浆中的纤维蛋白（原）降解产物含量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900020612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","09997","09996","BK0046","300406","BK1574","BK1100","159883","BK0239","BK1583","BK0077","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606792695","title":"九强生物(300406.SZ)发预减，预计2025年度归母净利润1.8亿元至2.18亿元，同比下降59.07%至66.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606792695","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606792695?lang=zh_cn&edition=full","pubTime":"2026-01-28 18:10","pubTimestamp":1769595043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润1.8亿元至2.18亿元，同比下降59.07%至66.21%;扣除非经常性损益后的净利润1.71亿元至2.11亿元，同比下降59.48%至67.16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"九强生物(300406.SZ)发预减，预计2025年度归母净利润1.8亿元至2.18亿元，同比下降59.07%至66.21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606734443","title":"九强生物新注册《MDC7600全自动凝血分析仪操作软件V1.0.0.000001》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606734443?lang=zh_cn&edition=full","pubTime":"2026-01-28 02:14","pubTimestamp":1769537654,"startTime":"0","endTime":"0","summary":"证券之星消息，近日九强生物新注册了2个项目的软件著作权，包括《MDC7600全自动凝血分析仪操作软件V1.0.0.000001》、《MDC3600全自动凝血分析仪操作软件V1.0.0.000001》等。今年以来九强生物新注册软件著作权2个。通过天眼查大数据分析，北京九强生物技术股份有限公司共对外投资了8家企业，参与招投标项目615次；财产线索方面有商标信息38条，专利信息200条，著作权信息6条；此外企业还拥有行政许可237个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800001304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0046","300406","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606167738","title":"九强生物（300406）披露持股5%以上股东减持致权益变动公告，1月27日股价下跌2.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606167738","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606167738?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:40","pubTimestamp":1769524827,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，九强生物报收于14.3元，较前一交易日下跌2.59%，最新总市值为83.84亿元。公告显示，公司持股5%以上股东ZHOU XIAOYAN女士因减持股份，持股比例由5.25%下降至4.99998%，不再属于持股5%以上股东。本次减持通过集中竞价交易方式进行，减持计划未违反相关法规及承诺。公司无控股股东和实际控制人，本次权益变动不触及要约收购，不导致控制权变更，不影响公司治理结构和持续经营。中金公司作为债券受托管理人发布本次临时事务报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700042132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0028","BK0046","BK0239","BK0077","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605108529","title":"1月21日九强生物发布公告，股东减持145.43万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2605108529","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605108529?lang=zh_cn&edition=full","pubTime":"2026-01-21 18:01","pubTimestamp":1768989683,"startTime":"0","endTime":"0","summary":"证券之星消息，1月21日九强生物发布公告《九强生物:简式权益变动报告书》，其股东ZHOU XIAOYAN于2025年12月11日至2026年1月20日间合计减持145.43万股，占公司目前总股本的0.248%，变动期间该股股价上涨1.95%，截止1月20日收盘报14.15元。股东增减持详情见下表：根据九强生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","300406","BK0028","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602674115","title":"九强生物：迈新生物已开始进行海外市场注册体系搭建","url":"https://stock-news.laohu8.com/highlight/detail?id=2602674115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602674115?lang=zh_cn&edition=full","pubTime":"2026-01-12 11:36","pubTimestamp":1768188966,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物01月12日在投资者关系平台上答复投资者关心的问题。公司的各项产品应申请国内外医保局关于创新医疗器械绿色快速通道快速拿证抢占市场。目前，迈新生物已开始进行海外市场的前期布局与注册体系搭建，具体的注册申请工作将根据产品成熟度和市场需求适时推进，敬请广大投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200011091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300406","BK0028","BK0046","BK0012","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602552174","title":"股市必读：九强生物（300406）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602552174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602552174?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:33","pubTimestamp":1768152787,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，九强生物报收于13.58元，上涨0.59%，换手率1.52%，成交量6.43万手，成交额8703.99万元。董秘最新回复投资者： 九强必须要改变了。一边是冰冷的公司股价。说明公司的产品、商业模式已经被资本抛弃了。随着最少够用等政策的发布量价齐跌，传统ivd行业的春天一去不复返。希望公司抛弃固化思维，拥抱新科技新模式，积极行动起来。当日关注点来自交易信息汇总：1月9日主力资金净流出1713.31万元，显示主力短期减持动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200000659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","BK0046","BK0077","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602375705","title":"九强生物：病理AI相关项目处于临床验证阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375705?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:52","pubTimestamp":1767963120,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物01月09日在投资者关系平台上答复投资者关心的问题。说明公司的产品、商业模式已经被资本抛弃了。公司高度认同科技浪潮对行业的重塑价值，也始终以主动变革应对行业结构性变化，病理AI相关项目是公司重点研发项目，当前，在研产品尚处于临床验证阶段，后续相关进展请以公司公告为准，敬请广大投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0239","BK0028","300406","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602439245","title":"股市必读：九强生物（300406）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602439245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602439245?lang=zh_cn&edition=full","pubTime":"2026-01-09 02:46","pubTimestamp":1767897971,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，九强生物报收于13.5元，上涨1.12%，换手率1.15%，成交量4.89万手，成交额6584.15万元。董秘最新回复投资者： 董秘您好！请问协议转让是否过户完成将在何时进行披露？交易信息汇总资金流向1月8日主力资金净流出200.61万元；游资资金净流出67.0万元；散户资金净流入267.61万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0012","BK0046","BK0077","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601588897","title":"九强生物（300406）披露取得医疗器械注册证书，1月5日股价上涨3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588897","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601588897?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:43","pubTimestamp":1767609833,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，九强生物报收于13.5元，较前一交易日上涨3.29%，最新总市值为79.15亿元。该股当日开盘13.14元，最高13.5元，最低13.0元，成交额达9626.05万元，换手率为1.7%。同日，九强生物发布公告称，公司近日收到北京市药品监督管理局颁发的三份《医疗器械注册证》，产品分别为铁测定试剂盒、轻链λ测定试剂盒和可溶性生长刺激表达基因2蛋白测定试剂盒，注册类别均为Ⅱ类，有效期均至2030年12月30日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500030839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","09996","BK1574","300406","BK0012","BK1100","09997","BK0028","BK1583","BK1222","BK0046","159883","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776028556974,"stockEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0398},{"period":"3month","weight":-0.1119},{"period":"6month","weight":-0.0939},{"period":"1year","weight":-0.1556},{"period":"ytd","weight":-0.0773}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京九强生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18058人(较上一季度减少2.48%)","perCapita":"23497股","listingDate":"2014-10-30","address":"北京市海淀区花园东路15号旷怡大厦5层","registeredCapital":"58630万元","survey":" 北京九强生物技术股份有限公司的主营业务是打造多元化、高质量体外诊断检测平台，目前拥有病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。公司的主要产品是病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。2025年1月14日，公司荣获“军事科学技术进步一等奖”。","listedPrice":14.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九强生物,300406,九强生物股票,九强生物股票老虎,九强生物股票老虎国际,九强生物行情,九强生物股票行情,九强生物股价,九强生物股市,九强生物股票价格,九强生物股票交易,九强生物股票购买,九强生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}